Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
WATERTOWN, Mass., March 03, 2017 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will report fourth quarter and full year 2016 financial results after the close of U.S. financial markets on March 8, 2017, and will host a conference call on Wednesday, March 8, 2017 at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
The call can be accessed by dialing (844) 831-4023 (U.S. and Canada) or (731) 256-5215 (international) and entering passcode 82825167. To access the live audio webcast, or the subsequent archived recording, visit the "Investor Relations - Events & Presentations" section of the Tetraphase website at www.tphase.com. The webcast will be recorded and available for replay on the Tetraphase website for 30 days following the call.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Argot Partners Maeve Conneighton 206-899-4940 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected]
